
May 2, 2025, 09:25
Myeloma Paper of the Day, May 2nd, suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: dFLC over 180 mg/L may no longer holds prognostic value in era of CyBorD/DaraCyBorD-based AL amyloidosis therapy and question utility of Mayo 2012 staging system in the era of highly effective chemo-immunotherapies.”
Title: Predictive Value of Free Light Chain Burden in Patients with AL Amyloidosis Treated with Bortezomib-Based Regimens
Authors: Brendan Saunders, Foteini Theodorakakou, Despina V Fotiou, Samuel Boullt, Benjamin Evans, Meletios Athanasios Dimopoulos, Efstathios Kastritis, Giada Bianchi.
You can read the Full Article on Blood Advances.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 2, 2025, 09:25
May 2, 2025, 08:58